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Abstract
Before any medicinal product is authorised for use in adults, it must undergo extensive
pharmaceutical consistency and stability tests, toxicological tests and clinical trials to ensure that it
is of high quality, safe and effective.
The same approach may not always be applied to medicinal products used to treat children.
Studies showed that over 50% of the medicinal products used in children may not have been tested
for use in this age group. The absence of suitable authorised medicinal products to treat conditions
in children results from the fact that pharmaceutical companies do not adapt medicinal products to
the needs of the paediatric population. This leaves health care professionals with no alternative
other than to use medicinal products "off-label" and to use unauthorised products with the
associated risks of inefficacy and/or adverse reactions.
The Regulation (EC) No 1901/2006 sets up a system of requirements, rewards and incentives,
together with horizontal measures, to ensure that medicinal products are researched, developed
and authorised to meet the therapeutic needs of children.
The Regulation is addressed to:
1. The pharmaceutical industry by setting out the legal framework for receiving rewards and
incentives by conducting clinical trials in the paediatric population.
2. The Member States to set out to support research into, and the development and availability of,
medicinal products for paediatric use.
3. The Community as funds for research into medicinal products for the paediatric population shall
be provided for in the Community budget in order to support studies relating to medicinal
products or active substances not covered by a patent or a supplementary protection certificate.
The legal framework for conducting clinical trials, including children/minors, is set up in Directive
2001/20/EC, the Clinical Trials Directive (CTD), for the European Union (EU). The CTD
establishes specific provisions regarding conduct of clinical trials, including multi-centre trials, on
human subjects involving medicinal products and in particular relating to the implementation of
good clinical practice. Compliance with this good practice provides assurance that the rights, safety
and well-being of trial subjects are protected, and that the results of the clinical trials are credible.
The CTD is addressed to all investigators conducting clinical trials including clinical trials in the
paediatric population and had to be applied accordingly.
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In the framework of the authorisation of medicinal products regulated by the Regulation (EC) No
726/2004 and Directive 2001/83/EC as amended and the CTD, and additional implementing
Directives and guidelines, the new Regulation (EC) No 1901/2006 is an important new piece of
legislation focusing on the requirements to improve the situation for the paediatric population.
All Regulations/Directives to be found:
http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol1_en.htm
Background
In contrast to the situation in adults, more than 50% of
the medicines used to treat the children of Europe have
not been adequately tested and are not authorised for use
in children [1]. Therefore the health and thereof the qual-
ity of life of the children of Europe may suffer from a lack
useful age appropriate medicinal products.
The paediatric population is not a homogeneous group it
encompasses several subsets defined in ICH guideline
E11: the pre term and term neonate from 0 to 27 days, the
infant from 1 month to 23 months, the child from 2 years
to 11 years and the adolescent from 12 up to 18 years [2].
Children are not miniature versions of adults. Due to age-
related differences in drug handling or drug effects which
may lead to different dose requirements to achieve effi-
cacy or to avoid adverse reactions, specific clinical trials in
paediatric populations are normally required. In addition,
there may be practical problems of administration e.g. dif-
ficulties swallowing tablets if a syrup is not available or,
more significantly, serious calculation errors when using
adult formulations to obtain paediatric dosages. Children
are a vulnerable group with developmental, physiological
and psychological differences from adults, which makes
age and development related research of medicines partic-
ularly important.
Although there may be concerns voiced about conducting
trials in the paediatric population, this has to be balanced
by the ethical issues related to giving medicines to a pop-
ulation in which they have not been tested and therefore
their effects, positive or negative, are unknown. In order to
address the concerns about trials in children it has to be
pointed that the requirements for the protection of the
paediatric population who take part in clinical trials in the
Community laid down in Directive 2001/20/EC of the
European Parliament and of the Council of 4th April 2001.
In terms of both public health and ethics, it is clearly pref-
erable to test medicines in children, in a safe and control-
led clinical trial environment, where the individual child
is protected and the studies generate data and information
for the benefit of the rest of the children of the EU than to
go on with the daily "experiments on children" that today
occur because such medicines for children have never
been designed and evaluated for this particular use [3].
In order to increase the availability of information on the
use of medicinal products in the paediatric population,
and to avoid unnecessary repetition of studies in the pae-
diatric population European database provided for in
Article 11 of Directive 2001/20/EC should include a Euro-
pean register of clinical trials of medicinal products for
paediatric use – part of the information – should be made
public by the EMEA.
The overall policy objective with the new Regulation is to
improve the health of the children of Europe by increasing
the research, development and authorisation of medicinal
products for use in children.
General objectives are to:
￿ increase the development of medicinal products for use
in children,
￿ ensure that medicinal products used to treat children are
subject to high quality research,
￿ ensure that medicinal products used to treat children are
appropriately authorised for use in children,
￿ improve the information available on the use of medic-
inal products in children.
￿ achieve these objectives without subjecting children to
unnecessary clinical trials and in full compliance with the
EU CTD.
To ensure that all the medicinal products required by chil-
dren fall within the scope of the proposal and to fully
understand the measures proposed, it is necessary to
break medicinal products down into three groups:
- medicinal products in development (not yet to be
authorised)
- authorised medicinal products still covered by patents or
supplementary protection certificatesChild and Adolescent Psychiatry and Mental Health 2008, 2:37 http://www.capmh.com/content/2/1/37
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- authorised medicinal products not covered by these
instruments.
The Regulation comprises several core elements in respect
to collection of information on medicinal products, sup-
ported by a variety of rewards and incentives and penal-
ties, the Paediatric Committee (PDCO) and transparency
measures.
1. CORE element: data collection and 
verification
The Regulation reflects on three different actual situations
for the collection of data for medicinal products in rela-
tion to the use in children.
The recommendation of the PDCO addressed to the MSs
regarding the collection of data in the off-label use as
required by Article 42 of the Regulation are published in
the EMEAs' web-site. This is an on-going tasks for the MSs
and no information is as today published.
Firstly the retrospective collection of information in
accordance with Article 45 where it obliges the marketing
authorisation holder of a medicinal product to provide all
information regarding clinical trials in children which are
already completed at latest by January 26 2008 to the
competent authorities. The submitted data and the refer-
ences to these data in the corresponding Package Leaflet
(PL) and Summary of Product Characteristics (SmPC) will
be evaluated in the framework of Paediatric Work-sharing
Programme hosted by the coordination group (CMD) [4].
Secondly all on-going clinical trials have to be submitted
within 6 months of their completion according to Article
46.
The third and far-reaching measures are laid down in Arti-
cles 7 and 8 of the Regulation.
Article 7 requires that by 26th July 2008 all applications of
new medicinal products only will be validated by the
competent authorities with a Paediatric Investigation Plan
(PIP) and results of studies according to this PIP or a PIP
deferral of a PIP waiver.
The same applies for extensions of an already authorised
medicinal product with a Supplementary Protection Cer-
tificate (SPC) or a Patent according to Article 8 from Jan-
uary 26th 2009 onwards.
An additional tool to improve the knowledge on medici-
nal products in the use of children is laid down in Article
30 the so-called Paediatric Use Marketing Authorisation
(PUMA) where for off patent medicinal products data
exclusivity are offered for authorised medicinal as an
incentive.
All information which will be collected in the different
routes of getting relevant recommendation to treat chil-
dren with a medicinal product will be included in the PL
and SmPC for each corresponding medicinal product in
question.
2. CORE element: rewards, incentives & 
penalties, and sanctions
2.1 Rewards and Incentives (Articles 36 – 40)
The Regulation contains a shared responsibility between
European Commission (EC) and Member States (MSs) in
respect of incentives for research and development of
medicinal products for paediatric use and for placing such
products on the market, within the framework of their
own powers and responsibilities.
The requirement for data in children applies to the current
procedures for marketing authorisation applications; the
reward for compliance with the requirement is an exten-
sion to the existing supplementary protection certificate;
for orphan medicinal products (OMP) the reward for
compliance with the requirement is two years added to
the existing market exclusivity; the new type of marketing
authorisation, the PUMA, utilises the current marketing
authorisation procedures.
2.1.1 EU
Patent protection, Supplementary Protection Certificate,
market exclusivity, data exclusivity
For new medicinal products or line extensions of existing
patented medicinal products, covered by a patent or a
SPC, if all the measures included in the agreed paediatric
investigation plan are complied with and if the product is
authorised in all MSs and if relevant information on the
results of studies is included in product information, the
six-month SPC extension will be granted.
Because the reward is for conducting studies in children
and not for demonstrating that a product is safe and effec-
tive in children, the reward will be granted even when a
paediatric indication is not granted.
For OMPs a two-year extra market exclusivity will be
rewarded.
Under the EU orphan drug Regulation, medicinal prod-
ucts designated as OMPs gain ten-years of market exclusiv-
ity on the granting of a marketing authorisation in the
orphan indication. Therefore it is proposed to extend the
ten-year period of orphan market exclusivity to twelve-Child and Adolescent Psychiatry and Mental Health 2008, 2:37 http://www.capmh.com/content/2/1/37
Page 4 of 7
(page number not for citation purposes)
years if the requirements for data on use in children are
fully met.
The PUMA will utilise existing marketing authorisation
procedures but is specifically for medicinal products
developed exclusively for use in children. By allowing
retention of the existing brand name and a benefit for the
data protection time of 10 years associated with a new
marketing authorisation will be rewarded.
2.1.2 Member States
The rewards and incentives included in the Regulation do
not preclude access of medicinal products being devel-
oped for children to other incentives or rewards by MSs. It
is within their respective spheres of competence, to pro-
vide other incentives for developing medicinal products
for paediatric use.
MSs are asked to provide information in this respect to the
EC by a given time point and are asked to update the EC
on a regularly basis.
2.2 Penalties and Sanctions (Article 49 – 50)
2.2.1 EU
At the EMEA's request, the Commission may impose
financial penalties for infringement of the provisions of
this Regulation or the implementing measures adopted
pursuant to it in relation to medicinal products author-
ised through the procedure laid down in Regulation (EC)
No 726/2004. The maximum amounts as well as the con-
ditions and methods for collection of these penalties shall
be laid down in accordance with the procedure referred to
in Article 51(2) of this Regulation.
The EC shall make public the names of anyone infringing
the provisions of this Regulation or of any implementing
measures adopted pursuant to it and the amounts of, and
reasons for, the financial penalties imposed.
2.2.2 Member States
At national level penalties for infringement of the Regula-
tion
Without prejudice to the Protocol on the Privileges and
Immunities of the European Communities, each MSs
shall determine the penalties to be applied for infringe-
ment of the provisions of this Regulation or the imple-
menting measures adopted pursuant to it in relation to
medicinal products authorised through the procedures
laid down in Directive 2001/83/EC and shall take all
measures necessary for their implementation. The penal-
ties shall be effective, proportionate and dissuasive.
The first inventory of Community and MSs rewards and
incentives to support research into, and the development
and availability of, medicinal products for paediatric use
according to Article 39 of the Regulation, was made public
on 30 July 2008 on the ECs web-site.
3. CORE element: implementation of the 
paediatric committee (PDCO)
Composition and tasks of the PDCO (Article 5–6)
3. 1. Composition
Regarding the composition of the new PDCO two aspects
have to been taken into account by ensuring the continu-
ity in the scientific and ethical considerations of the
medicinal product in question.
The continuity of the scientific aspects is assured by the
requirement that 5 member of the PDCO are also mem-
bers of the Committee for Human Medicinal Product
(CHMP) the opinion taking body in a marketing authori-
sation procedure for medicinal products. For the moment
only the 4 members from Romania, Estonia, Lithuania
and Slovak Republic are building the link. For the second
aspect patients/parents and health professionals repre-
sentatives are to be included in the PDCO. Each member
has an alternate.
Information on the PDCO members and alternates are to
be find on the EMEAs' web-site http://
www.emea.europa.eu/htms/general/contacts/PDCO/
PDCO.html
3.2 Tasks
Detailed information will be found in the references given
in brackets after each bullet point.
The PDCO is asked to
￿ Assess and formulate opinions on PIPs, waivers and
deferrals including consideration of whether proposed
studies can be expected to be of significant therapeutic
benefit and/or fulfil a therapeutic need of the paediatric
population
￿ Advice on surveys regarding existing paediatric use [5].
￿ Support of the EMEA regarding the network of paediat-
ric experts [6].
￿ Providing advice (on request) [7].
￿ Establishment of an inventory of paediatric needs [8].
The Regulation includes provisions for funding of studies
into off-patent medicinal products. This funding, pro-
vided through the EU Framework programmes, should
cover the development of off patent medicinal productsChild and Adolescent Psychiatry and Mental Health 2008, 2:37 http://www.capmh.com/content/2/1/37
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with a view to the submission of a Paediatric Use Market-
ing
The objective of the priority list is to provide the basis for
the work programme for the Third Call for Framework
Programme 7 of the European Commission. It ensures
that funds are directed into research of medicinal products
with the highest need in the paediatric population.
The list of off-patent products has been revised by the
PDCO and was agreed on 29/08/2008.
The list includes only products considered to be off-pat-
ent, i.e. not covered by a basic patent or a supplementary
protection certificate. Information on the off-patent status
is not guaranteed by EMEA. It should be noted that infor-
mation on the authorisation status as well as on available
paediatric formulations of medicinal products is very lim-
ited and not available for all European Member States.
Users of this list are therefore advised to check the patent
and authorisation status of the medicinal products of
interest.
The methodology used to establish the list was based as
much as possible on evidenced based medicine. It is how-
ever acknowledged that identification of priorities for
research into medicinal products for paediatric use is
partly based on subjective criteria and that identified pri-
orities may change over time.
￿ Recommendation on a symbol
Article 32 of the Regulation (EC) No 1901/2006 foresees
that medicinal products granted a marketing authorisa-
tion for a paediatric indication shall display a symbol for
their identification. Following this Regulation, the selec-
tion of the symbol by the EC is to be based on a recom-
mendation of the EMEAs' PDCO. The Regulation provides
for the Commission to select the symbol by 26 January
2008 and make the symbol public. On the 20th of
December 2007 the PDCO adopted its recommendation
regarding the symbol by a majority vote of eighteen
against four. The adopted recommendation is that
"As a consequence of its analysis balance of benefits and
risks of the symbol, the Paediatric Committee was unable
to recommend to the EC any symbol for which the bene-
fits would outweigh the risks identified and dominated by
potentially fatal medication errors".
Publication of this announcement serves to inform stake-
holders that on the basis of this recommendation, the EC
is at present not in a position to select a symbol and the
provisions of Article 32 of the Regulation cannot therefore
be implemented [3].
It is unclear for the moment in which way this provision
shall be handled by the MSs as this also apply to medici-
nal products authorised before the entry into force of this
Regulation.
3.3 Paediatric Investigation Plan (PIP)
The new key element of the Regulation is the early
involvement of a company independent scientific and
regulatory body, the PDCO, in the research and develop-
ment programme of a medicinal product by the require-
ment to receive an agreement/a decision on the proposed
process for a new medicinal product. Which contains two
elements either to get a waiver or an agreement on the
clinical trials, and if necessary including a deferral, in chil-
dren to be included in the development programme.
The aim is to ensure that the necessary data are generated
determining the conditions in which a medicinal product
may be authorised to treat the paediatric population. The
timing and the measures proposed to assess quality, safety
and efficacy in all subsets of the paediatric population that
may be concerned shall be presented in a PIP dossier. In
addition, any measures to adapt the formulation of the
medicinal product for its use in the paediatric population
shall be included.
The content of information which shall be provided in a
PIP is set out in the 'Commission guideline on the format
and content of applications for agreement or modifica-
tion of a paediatric investigation plan and requests for
waivers or deferrals and concerning the operation of the
compliance check and on criteria for assessing significant
studies' [3].
4. Transparency and information
(Article 41 and 28)
One of the objectives of the Regulation is to increase the
information available on the use of medicines for chil-
dren. Through increased availability of information, the
safe and effective use of medicinal products for children
can be increased so promoting public health. In addition,
availability of this information will help prevent the
duplication of studies in children and the conduct of
unnecessary studies in children. One of the measures is to
build on the public health work of the CTD. The CTD
establishes a Community database of clinical trials
(EudraCT).
4.1 Transparency regarding clinical trials
Article 41 of the Regulation requires the Commission to
draw up guidance on the nature of the information on
paediatric clinical trials to be entered into the database of
clinical trials (EudraCT), created by the CTD, on which
information shall be made available to the public, on howChild and Adolescent Psychiatry and Mental Health 2008, 2:37 http://www.capmh.com/content/2/1/37
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clinical trials results shall be submitted and be made pub-
lic and on the EMEAs' responsibilities and tasks in this
regard.
The aim of the new Regulation is also to increase transpar-
ency in respect to clinical trials in children in all phases of
the progress, beginning from the planning and recruiting
of patients to the on-going and finalised studies.
This requirements goes much beyond the requests pre-
sented in the CTD where the access to the European data-
base on clinical trials is limited to the competent
authorities of the MSs, the EMEA and the EC and in Regu-
lation (EC) No. 726/2004 Article 57 which is only reflect-
ing on the publication of information on clinical trials for
already authorised medicinal products.
The EC published a consultation on a "Draft Guidance on
the information concerning paediatric clinical trials to be
entered into the EU Database on Clinical Trials (EudraCT)
and on the information to be made public by the EMEA,
in accordance with Article 41 of Regulation No. (EC)
1901/2006".
4.2 Information
Article 28 of the Regulation sets out where authorisation
is granted, the results of all those studies shall be included
in the SmPC and, if appropriate, in the PL of the medici-
nal product, provided that the competent authority deems
the information to be of use to patients, whether or not all
the paediatric indications concerned were approved by
the competent authority. Where a marketing authorisa-
tion is granted or varied, any waiver or deferral which has
been granted pursuant to this Regulation shall be
recorded in the SmPC and, if appropriate, in the PL of the
medicinal product concerned. If the application complies
with all the measures contained in the agreed completed
PIP and if the summary of product characteristics reflects
the results of studies conducted in compliance with that
agreed PIP, the competent authority shall include within
the marketing authorisation a statement indicating com-
pliance of the application with the agreed completed PIP.
For the purpose of the application of Article 45(3), this
statement shall also indicate whether significant studies
contained in the agreed PIP have been completed after the
entry into force of this Regulation.
This has to be transposed by the revision of the guideline
on the SmPC. In this respect to EC realised a public con-
sultation in the beginning of 2008. The finalisation of the
revision is still pending.
5. Supporting measures – guidelines
5.1. Guideline on Ethical consideration
To contribute to the protection of children who are the
subject of clinical trials a specific recommendation was
deemed to be necessary. Furthermore, the recommenda-
tions are intended to facilitate a harmonised application
of rules on clinical trials across the EU and thereby facili-
tate the conduct of clinical trials in the EU.
Therefore the EC realised a guideline on 'Ethical consider-
ations for clinical trials on medicinal products conducted
with the paediatric population'.
Recommendations of the ad hoc group for the develop-
ment of implementing guidelines for Directive 2001/20/
EC relating to good clinical practice in the conduct of clin-
ical trials on medicinal products for human use [3].
5.2 Guidelines on clinical trials
Additionally all guidelines containing recommendation
on clinical trials for specific indication have to be carefully
scrutinized and updated in respect to the requirements for
conducting clinical trials in the paediatric population tak-
ing into account the different age groups [9].
Conclusion
The Regulation (EC) No 1901/2006 sets up a system of
requirements, rewards and incentives, together with hori-
zontal measures, to ensure that medicinal products are
researched, developed and authorised to meet the thera-
peutic needs of children.
The legal framework for conducting clinical trials, includ-
ing children/minors, is set up in Directive 2001/20/EC for
the European Union.
Harmonised ethical considerations are published by the
European Commission to been taken into account by all
interested parties conducting clinical trials in the paediat-
ric population.
The Regulation includes provisions for funding of studies
into off-patent medicinal products. This funding, pro-
vided through the EU Framework programmes, should
cover the development of off patent medicinal products
with a view to the submission of a Paediatric Use Market-
ing
It is now of utmost importance to set the scene in the
European Union to convince the paediatric patients, par-
ents, caretaker, nurses and doctors to assent and consent
in participating in clinical trials for the benefit of the pae-
diatric population by large.
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